WuXi AppTec Reports No Mass Cancellations, Adds Over 300 New Clients in Q1; Jinhe Bio Secures Tens of Millions in Angel Funding for Cutting-Edge Enzyme-Electro Technology Platform

1. WuXi AppTec has not experienced a significant number of order cancellations; in the first quarter, it added over 300 new clients, with Europe and America accounting for 40%.

At WuXi AppTec's Q1 earnings meeting today, WuXi AppTec stated that based on the data from the first quarter, there has been no significant cancellation of orders by clients. Only a very small number of early-stage R&D clients canceled certain services due to disturbances caused by the draft proposal. The company has a large customer base, and different customers will make different considerations based on their own situations. In Q1, about 40% of over 300 new customers came from Europe and America, nearly 50% were new customers from China, and the remaining 10% were from other regions. In terms of revenue contribution, the income contribution from European and American customers was larger.

2. OxSyns Technology Co., Ltd. Completes Multi-Million Angel Financing Round to Build an Internationally Advanced Enzyme-Electric Technology Platform

On April 29, 2024, OxSyns Technology Co., Ltd. completed an angel round of financing worth tens of millions. This round was led by CDH VGC and Tianze Capital, with participation from Guohong Jiaxin and INNO Angel Fund. The company is a leading global developer of enzyme-electrode coupling technology, and its cell-free enzymatic electrosynthesis technology will serve as the "next-generation synthetic biology technology," profoundly impacting the development of the synthetic biology industry.

3. Hebei's Biomedical Industry Achieves "Accelerated Growth," Revenue Exceeds 100 Billion in 2023

Hebei's Biopharmaceutical Industry Revenue Breaks Through 100 Billion Yuan: Policy Support and Corporate Innovation Jointly Drive Growth; Leading Companies like CSPC and Yiling Pharmaceutical Continue to Increase R&D Investment, Demonstrating Strong Future Innovation Potential.

4. Shengjing x Vazyme Launch "Shengzan Innovation Industry Incubation and Cultivation Platform," Building an Innovation Engine in the Life Sciences Field

Shengjing and Vazyme Jointly Launch the "Shengzan Innovation Industry Incubation and Cultivation Platform" to Bring Together Scientific Research, Industry, and Venture Capital Resources, Accelerating the Growth of Innovative Projects in the Life Sciences Field and Injecting More Momentum into Industrial Development. The platform will leverage the strengths of both parties to provide full support for the industrialization of scientists' intellectual property, continuously discovering and empowering talent through initiatives like the Life Sciences Innovation and Entrepreneurship Challenge.

5. Focusing on Respiratory Anti-infection and Pain Fields, Andikang (Wuxi) Biotechnology Co., Ltd. Completes Hundreds of Millions of Yuan in Series A Financing

Andikang (Wuxi) Biotechnology Co., Ltd. Completes Hundreds of Millions of Yuan in Series A Financing, Focusing on Respiratory Anti-Infection and Pain Fields, Developing Multiple Innovative Drugs. Investment institutions include Simcere Pharmaceutical Group, among others. The funds will be used to advance product development and clinical trials. Previous Pre-A round and strategic financing have been completed.

6. Securing Over 100 Million Yuan in Financing, 100% CR, What Makes Leman Biotech's Metabolism-Enhanced Cancer Immunotherapy Stand Out

On April 30, 2024, Leman Biotech Co., Ltd., located in Shenzhen, secured multi-million-level funding from the Investment Institute of the Comprehensive National Science Center for Health in Hefei. The company is an innovative enterprise specializing in addressing T cell exhaustion and developing metabolism-enhanced tumor immunotherapy drugs. It has pioneered Immune Metabolic Reprogramming Technology (Meta 10) and established a proprietary technology platform for the discovery, research, and production of biologic macromolecule drugs and novel immune cell therapies. Additionally, leveraging artificial intelligence (AI) technology from XtalPi, the company has further developed an AI-driven new drug development platform.